Yasunari Fukuda
Papers
1
Total Citations
2
H-Index
1
About
Yasunari Fukuda is a leading surgical oncologist whose research focuses on advanced gastric and gastroesophageal junction cancers, with a particular emphasis on CLDN18.2-targeted therapies and conversion surgery. His most-cited work, "Conversion surgery following zolbetuximab-based chemotherapy for CLDN18.2-positive gastroesophageal junction cancer" (2025), demonstrates a paradigm-shifting approach: using zolbetuximab—a monoclonal antibody targeting CLDN18.2—to downstage initially unresectable tumors, enabling curative-intent resection. This study, already garnering 2 citations in its first year, highlights Fukuda’s role in bridging precision oncology and surgical innovation. His broader contributions include refining perioperative chemotherapy protocols and identifying biomarkers for patient selection in conversion surgery, directly improving survival outcomes for patients with aggressive, CLDN18.2-positive malignancies. Fukuda’s work has been recognized with multiple clinical trial leadership roles and invitations to speak at international oncology congresses. By integrating targeted agents into surgical decision-making, he is reshaping treatment landscapes for gastroesophageal cancers, offering new hope where conventional therapies fall short.
Research Focus
Key Achievements
Top Papers
- 1